Pro Medicus signs Echo IQ deal to boost AI cardiology offering

The Pro Medicus Ltd (ASX: PME) share price is in focus after the company announced a binding Heads of Agreement with Echo IQ for a finance facility and reseller agreement, aiming to expand its AI-driven cardiology solutions.

What did Pro Medicus report?

• Signed a binding Heads of Agreement with Echo IQ Ltd for a financing arrangement
• Agreement includes a reseller arrangement for Echo IQ’s AI algorithms in cardiology
• Focus on commercialising solutions for aortic stenosis and heart failure detection
• Definitive agreements expected within 20 business days or the transaction may lapse

What else do investors need to know?

Pro Medicus is broadening its AI strategy by adding third-party algorithms to its Visage 7 Cardiology platform, alongside in-house and partner-developed solutions. The finance facility for Echo IQ is designed to help accelerate its AI offerings, particularly in key disease areas.

While the Heads of Agreement sets out the framework, the deal is subject to final legal agreements. Pro Medicus has committed to updating shareholders once these are completed or if negotiations end without a deal.

What did Pro Medicus management say?

Chief Executive Officer Dr Sam Hupert said:

In addition to providing financial backing, we are looking to offer our Visage 7 Cardiology customers the option of Echo IQ’s technology. This is in line with our AI strategy of offering a curated suite of algorithms that will be a mixture of algorithms created by us, those created in conjunction with our clinical partners and 3rd party algorithms such as Echo-IQ.

What’s next for Pro Medicus?

Pro Medicus plans to proceed with negotiating definitive agreements with Echo IQ over the next 20 business days. The move supports its ambition to grow market offerings and provide innovative, AI-powered cardiology solutions to its customers.

If successful, the agreement will further expand Pro Medicus’ AI capabilities and commercial reach, reinforcing its growth strategy in health imaging.

Pro Medicus share price snapshot

Over the past 12 months, Pro Medicus shares have declined 35%, trailing the S&P/ASX 200 Index (ASX: XJO), which has risen 3% over the same period.

View Original Announcement

The post Pro Medicus signs Echo IQ deal to boost AI cardiology offering appeared first on The Motley Fool Australia.

More reading

• Ventia Services appoints new CEO in leadership succession
• A2 Milk declares $300 million special dividend after securing China approval
• 2 ASX 200 shares I’d buy for powerful growth
• 5 things to watch on the ASX 200 on Thursday
• 3 buy-rated ASX tech shares with bright futures

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.